Neuropace Inc
NASDAQ:NPCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neuropace Inc
Total Equity
Neuropace Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuropace Inc
NASDAQ:NPCE
|
Total Equity
$19m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Equity
$24.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Equity
$10.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Equity
$22.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Equity
$52.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Equity
$17.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
Neuropace Inc
Glance View
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
See Also
What is Neuropace Inc's Total Equity?
Total Equity
19m
USD
Based on the financial report for Dec 31, 2025, Neuropace Inc's Total Equity amounts to 19m USD.
What is Neuropace Inc's Total Equity growth rate?
Total Equity CAGR 3Y
-18%
Over the last year, the Total Equity growth was 138%. The average annual Total Equity growth rates for Neuropace Inc have been -18% over the past three years .
